Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy.

ABSTRACT:

Aim

Major depressive disorder is considered one of the most frequent diseases in the general population, and treatment-resistant depression (TRD) represents the subset with more significant clinical and social impact. Large, robust phase III studies have shown safety and efficacy of esketamine nasal spray plus SSRI/SNRI antidepressants (ADs) compared with SSRI/SNRI plus placebo nasal spray in patients with TRD. The main aim of this study was to perform a cost-utility analysis comparing esketamine plus ADs with ADs alone in TRD patients, from the societal perspective in Italy. A secondary analysis focused on the National Healthcare Service (NHS) perspective.

Methods

A Markov multistate model has been developed to estimate quality-adjusted life years and economic outcomes of b

SUBMITTER: Rognoni C 

PROVIDER: S-EPMC9883339 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature